A major consolidation in the psychedelic medicine space signals that brain-focused treatments are moving from experimental to mainstream, with a newly merged clinic network now positioned to rapidly scale emerging therapies as they gain regulatory approval. Radial, a neurotech-focused clinic operator, has acquired Mindful Health Solutions' management services organization, creating a combined network of 27 clinics and over 100 clinicians across seven states. The deal reflects growing maturity in psychedelic-assisted treatment markets and suggests that patients seeking alternatives to traditional antidepressants are driving demand for precision brain medicine.

What Is Driving Consolidation in Psychedelic Medicine?

The psychedelic medicine market has grown substantially in recent years. Esketamine and ketamine treatments are already worth an estimated $1.5 billion and $3.5 billion respectively, while transcranial magnetic stimulation (TMS), a non-drug brain treatment, is growing at nearly 8% annually and is on track to exceed $500 million by 2030. This financial momentum reflects both clinical evidence and patient demand for faster-acting, more effective treatments than traditional psychiatric medications.

The regulatory environment has also shifted. The federal government has softened its stance on psychedelic medicines, creating an opening for new treatments to enter the market in coming years. Radial's leadership expects psilocybin, the active compound in magic mushrooms, to gain FDA approval for depression and cluster headache, among other conditions.

How Will the Merged Network Improve Patient Care?

• Faster Access: The combined organization aims to reduce wait times for first appointments by integrating technology and streamlining scheduling across all 27 clinics, addressing a major barrier to care in mental health and neurology.
• Broader Treatment Options: Patients will gain access to a unified toolkit of FDA-cleared and emerging therapies, including accelerated TMS protocols, esketamine (Spravato), ketamine therapy, and specialized neurofeedback treatments for PTSD.
• Standardized Clinical Excellence: The merger enables Radial to scale its digital infrastructure, clinical decision support AI (RadialOS), and evidence-based care protocols across Mindful Health Solutions' existing practice sites, ensuring consistent quality regardless of location.

Dr. Owen Muir, Radial's co-founder and chief scientific officer, explained the strategic rationale: "What we were looking for wasn't just to acquire a bunch of clinics. It was to scale our technology workflow and philosophy of patient care. We think of every patient as the customer and focus on their experience as the north star". Mindful Health Solutions shared this patient-centered philosophy but lacked the technology infrastructure to deliver the seamless experience modern patients expect.

Owen Muir, Radial's co-founder and chief scientific officer

"What we were looking for wasn't just to acquire a bunch of clinics. It was to scale our technology workflow and philosophy of patient care," said Dr. Owen Muir.

Dr. Owen Muir, Co-founder and Chief Scientific Officer, Radial

What Treatments Will Be Available at the Merged Network?

The combined clinic network will systematically expand access to several FDA-cleared and investigational treatments based on insurance coverage and clinical appropriateness. Currently available offerings include the SWIFT protocol from BrainsWay (an accelerated TMS treatment), Ampa One TMS, PRISM EEG-fMRI neurofeedback for PTSD, ProlivRx for depression, and Magnus Medical's SAINT treatment, which uses fMRI imaging to precisely target brain regions for stimulation.

Beyond these established therapies, Radial is actively conducting clinical trials for emerging treatments. One notable trial involves transcranial focused ultrasound developed by Sanmai, a startup backed by venture capitalist Reid Hoffman, for people with Parkinson's disease and generalized anxiety disorder. The network has also pioneered clinical delivery of esketamine (Spravato) and ketamine therapy, treatments that are already generating billions in annual revenue.

The acquisition brings together leadership with deep expertise in psychedelic medicine. Dr. Alison McInnes, Mindful Health Solutions' director of psychedelic medicines, and Dr. Tobias Marton, the organization's chief medical officer, are recognized as leaders in the field. Notably, McInnes previously worked with Radial's Chief Product Officer Dr. Carlene MacMillan for five years at Osmind, a specialized electronic health record system designed for psychedelic clinics, creating natural alignment between the organizations.

How Does This Reshape Brain Medicine as a Specialty?

Muir describes the merged entity as pioneering a cross-disciplinary care model that transcends traditional medical specialties. Historically, physicians train in specific areas like psychiatry, neurology, or pain medicine before practicing within those silos. Radial's approach instead organizes care around evidence of which treatments work best for specific brain disorders, regardless of the clinician's original training.

This represents a fundamental shift in how brain medicine might be practiced. Sleep medicine offers a template: it already incorporates clinicians trained in pulmonary critical care, neurology, and psychiatry working collaboratively. Muir suggests that migraine management, movement disorders, depression, PTSD, and other conditions should be viewed as part of a broader category of brain medicine rather than isolated psychiatric or neurological problems.

"There are so many things that we can do with our tools. And what we're building is a way for clinicians to get comfortable with and great at using novel therapeutics that have a better safety and efficacy profile than anything that's ever come before," explained Dr. Muir.

Dr. Owen Muir, Co-founder and Chief Scientific Officer, Radial

What Role Do Insurance Companies Play in Scaling These Treatments?

Insurance coverage remains a critical bottleneck for expanding access to psychedelic and advanced brain medicine treatments. Regional health plans have begun covering these therapies as clinical evidence accumulates. Premera Blue Cross Blue Shield in Washington covers SWIFT, while Blue Cross of California covers SAINT treatment. The merged Radial network accepts insurance from Medicare, TRICARE (military health insurance), the Veterans Affairs system, Aetna, Cigna, UnitedHealthcare, and various Blues plans.

Muir noted that payers require scale before committing to broader coverage policies. "Payers need to see scale in order to justify larger coverage policies, because they don't want to negotiate onesie-twosie contracts," he stated. The acquisition provides exactly that scale: 27 clinics and over 100 clinicians create a network large enough to negotiate value-based contracts with major insurers. These contracts tie reimbursement to better outcomes, such as reducing psychiatric hospitalizations, which generate substantial downstream costs for health systems.

Muir

The financial case is compelling. Reducing emergency psychiatric hospitalizations through effective outpatient treatments like ketamine therapy or esketamine saves money for both patients and health plans. Muir emphasized that "we need to have interventions that work and work fast to keep people out of settings where they are not best served," pointing to recent research documenting the health and economic costs of psychiatric hospitalization.

Muir

What Does This Mean for Patients Seeking Psychedelic Therapy?

For patients interested in psilocybin therapy, MDMA-assisted therapy, or other psychedelic treatments currently in clinical trials, the consolidation signals that infrastructure is being built now to deliver these therapies at scale once they receive FDA approval. Radial's leadership explicitly stated they are "getting ready together" for the arrival of psychedelic medicines in the market. The merged network's 27 clinics, unified technology platform, and experienced clinical leadership position it to rapidly integrate new treatments as regulatory pathways clear.

The acquisition also reflects a broader market reality: the total addressable market for brain medicine extends far beyond mental health alone. Muir noted that "brain disorders is a bigger TAM [total addressable market] than mental health," suggesting substantial room for multiple companies to succeed with different approaches. This competitive landscape may ultimately benefit patients through innovation and improved access.

Muir